BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Valentis, Inc. (VLTS) Announces Temporary Adjournment of Annual Meeting of Stockholders Until July 12, 2007


6/29/2007 11:46:02 AM

BURLINGAME, Calif., June 28 /PRNewswire-FirstCall/ -- Valentis, Inc. announced today that its 2007 Annual Meeting of Stockholders, originally scheduled for 10:00 a.m., Pacific time, on Thursday, June 28, 2007, was adjourned due to the fact that there were not adequate shares present at the meeting, either represented in person or by proxies previously received by Valentis, to establish the quorum required to proceed with the meeting. No business was transacted prior to the adjournment. The meeting was adjourned until 10:00 a.m., Pacific time, Thursday, July 12, 2007 at the offices of Valentis, 533 Airport Blvd., Suite 400, Burlingame, California 94010.

About Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for PAD. On July 11, 2006, Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. Additional information about Valentis can be found at http://www.valentis.com.

Valentis, Inc.

CONTACT: Ben McGraw of Valentis, Inc., +1-650-697-1900, IR@valentis.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES